PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma-Reference-Cited by-同舟云学术

PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma

Published:2014-09-20 Issue:2 Volume:42 Page:215-221
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Alcantara Marion,Dupuis Jehan,Mareschal Sylvain,Julian Anne,Cottereau Anne Ségolène,Becker Stéphanie,Dubois Sydney,Oberic Lucie,Huynh Anne,Meignan Michel,Laurent Guy,Tilly Hervé,Haioun Corinne,Ysebaert Loïc

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-014-2896-2.pdf

Reference34 articles.

1. Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2008.

2. Gribben JG. How I treat indolent lymphoma. Blood. 2007;109:4617–26.

3. Brice P, Bastion Y, Lepage E, Brousse N, Haïoun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997;15:1110–7.

4. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–32.

5. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42–51.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Age and lymphocyte/monocyte ratio as prognostic factors for autologous transplantation in the treatment of patients with follicular lymphoma;Journal of International Medical Research;2024-02

2. Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study;HemaSphere;2023-02-21

3. Standardized classification schemes in reporting oncologic PET/CT;Frontiers in Medicine;2023-01-26

4. PET/CT zur Beurteilung des Therapieansprechens bei aggressiven Lymphomen;Angewandte Nuklearmedizin;2022-03

5. Prognostic Value of 2-Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography/Computed Tomography after Autologous Hematopoietic Stem Cell Transplantation in Lymphoma Using Deauville Scores;Contrast Media & Molecular Imaging;2021-04-15